News
QIAGEN’s QuantiFERON®-TB Gold Plus to be Adopted for Latent TB Testing in Nigeria
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Nigeria, the country with the largest population in Africa and one of the world’s 30 high-disease burden countries for
ICON Acquires MedPass International
ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device industries, today announced that it has
QIAGENs QuantiFERON®-TB Gold Plus als Test auf latente TB wird in Nigeria eingeführt
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute bekannt gegeben, dass Nigeria, das Land mit der größten Bevölkerung und eines der 30 Länder mit der höchsten Tuberkuloselast, im Rahmen
New International Consensus Statement Proposes “Difficult-to-treat Depression” as a More Clinically Useful Definition than “Treatment-Resistant Depression”
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, commends the recent international consensus statement published in the Journal of Affective Disorders for
Premier Inc. ProvideGx™ Program Partners with Pfizer Inc. to Provide Corvert® and Vincristine to Providers
Premier Inc. (NASDAQ: PINC), through its ProvideGx™ program, has partnered with Pfizer Inc. to supply Corvert® (ibutilide fumarate injection) and Vincristine Sulfate Injection, USP, to healthcare
Chemed Reports Fourth-Quarter 2019 Results
Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest
Medicare ACOs in Premier Inc. Collaborative Outperform Peers in Shared Savings by 21 Percent
Medicare Accountable Care Organizations (ACOs) participating in the Premier Inc. (NASDAQ: PINC) Population Health Management Collaborative (PHMC) have outperformed their peers by 21 percent in
Xencor to Host Fourth Quarter and Full Year 2019 Financial Results Webcast and Conference Call on February 24, 2020
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that it will
Canopy Growth: Das war der Befreiungsschlag!
Wie ein zu Barrons gehörendes bedeutendes Online-Finanzportal berichtet, würden die Anleger billiges Marihuana bevorzugen. Canopy Growth (WKN: A140QA) sei dabei derjenige Branchenplayer, der im
Canopy Growth: Was Aurora kann...
...kann Canopy Growth (WKN: A140QA) schon lange. Nein, Canopy kann es sogar viel besser. Der Cannabis-Marktführer meldet heute Quartalszahlen, die im Gegensatz zu den Horrorzahlen von Aurora
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2019 Results and Provides 2020 Guidance
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the fourth-quarter and full-year 2019 and provided guidance for 2020. For the quarter, revenue was $691.1
Xencor to Present at Upcoming Investor Conferences
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that company
Aimmune Licenses Exclusive Worldwide Rights to Xencor’s XmAb®7195 for the Development of Next-Generation Food Allergy Treatments
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, announced it has granted an
QIAGEN meldet Ergebnisse für das vierte Quartal und das Geschäftsjahr 2019
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die Ergebnisse der operativen Tätigkeit für das vierte Quartal und das Gesamtjahr 2019 bekannt.
„QIAGENs Ergebnisse des vierten
QIAGEN Reports Results for Fourth Quarter and Full-Year 2019
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results of operations for the fourth quarter and full-year 2019.
“QIAGEN’s performance for the fourth quarter and full-year 2019
Premier Inc. to Acquire Acurity and Nexera Businesses from the Greater New York Hospital Association
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today announced that it has entered into a definitive agreement to acquire substantially all the assets and certain
Premier Inc. Reports Fiscal 2020 Second-Quarter Results
Premier Inc. (NASDAQ: PINC) today reported financial results for the fiscal 2020 second quarter ended Dec. 31, 2019.
All results presented in this press release reflect continuing operations
QIAGEN führt FFPE- und Flüssigbiopsie-PIK3CA-Diagnostika in Europa ein, um die Präzisionsmedizin bei fortgeschrittenem Brustkrebs zu verbessern
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die CE-Kennzeichnung und die Einführung des therascreen® PIK3CA RGQ PCR-Kits in Europa zur Identifizierung von
QIAGEN Launches FFPE and Liquid Biopsy PIK3CA Diagnostics in Europe to Enhance Precision Medicine in Advanced Breast Cancer
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the CE-marking and launch of its therascreen® PIK3CA RGQ PCR Kit in Europe as an aid in identifying breast cancer patients
Acceleron Pharma: Bluthochdruck!
Die Aktie von Acceleron Pharma (WKN: A1W5LE) gehört heute zu den ganz großen Gewinnern am US-Aktienmarkt und kann um sage und schreibe mehr als +50% zulegen.
Dabei handelt es sich bei Acceleron
LivaNova to Host Conference Call for Fourth Quarter and Full-Year 2019 Results
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its fourth quarter and full-year 2019 results on Wednesday, Feb. 26
CommonSpirit Health Chooses Premier Inc. to Clinically Integrate its Newly Merged Supply Chain
CommonSpirit Health will be partnering with Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, to achieve operational excellence as it undergoes the complex integration of its
Evotec: Neue Top-Allianz – Anleger im Glück
Der News-Reigen setzt sich fort: Mit der auf Krebstherapien spezialisierten Indivumed initiiert Evotec (WKN: 566480) eine zweite Forschungsallianz, wie der TecDAX-Konzern heute mitteilt.
Konkret
Charles River Laboratories Schedules Fourth-Quarter 2019 Earnings and 2020 Guidance Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2019 financial results and provide 2020 guidance on Tuesday, February 11th, before the market
Allegheny General Hospital Partners with Omnicell to Automate Sterile Compounding
Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced that Allegheny General Hospital